Neurol. praxi. 2022;23(6):453-460

Application of antiCGRP prophylaxis episodic and chronic migraines in praxis

MUDr. Petra Migaľová
Centrum pro diagnostiku a léčbu bolestí hlavy, Neurologická klinika FN Ostrava a LF Ostrava

Migraine is the third most common neurological disease. It i also one of the most disabling disease in the world. They are around one million patients with migraine in the Czech Republic. At least 50 000 women and men suffer from chronic migraine. Since 1993, we have a specific acute antimigraine drug, triptans. Since 2020, targeted biological treatment has been available, which significantly reduces the number of migraine attacks and improves the patient's quality of life.

Keywords: episodic and chronic migraine, prophylactic treatment, anti CGRP treatment.

Received: June 23, 2022; Revised: July 13, 2022; Accepted: July 28, 2022; Prepublished online: July 28, 2022; Published: December 2, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Migaľová P. Application of antiCGRP prophylaxis episodic and chronic migraines in praxis. Neurol. praxi. 2022;23(6):453-460.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Diener H Ch, Tfelt­‑Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis Results from a placebo­‑controlled trial with propranolol as an active control. J Neurol. 2004;251:943-950. DOI 10.1007/s00415-004-0464-6. Go to original source... Go to PubMed...
    2. Edvisson L. the CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58(Suppl. 1):33-47. doi: 10.1111/head.13305. Go to original source... Go to PubMed...
    3. Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121-130 Go to original source... Go to PubMed...
    4. Goadsby P, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiatry. 2002;72(Suppl. 2):ii6-ii9. Go to original source...
    5. Goadsby PJ, Edvinsson L, Ekman R Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183-187. doi 10.1002/ana. 410280213. Go to original source... Go to PubMed...
    6. Hargreaves R, Olesen J. Calcitonin gene­‑related peptide modulators - the history and renaissance of new migraine drug class. Headache. 2019;59(6):951-970. doi:10.1111/head.13510. Go to original source... Go to PubMed...
    7. Hepp, Z, Dodick DW, Varon SF, et al. Adherence to oral migraine­‑preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-488. doi: 10.1177/0333102414547138. J Headache Pain. 2018;19(1):13. Go to original source... Go to PubMed...
    8. Honkasalo ML, Kaprio J, Winter T, et al. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache. 1995;35(2):70-78. Go to original source... Go to PubMed...
    9. Chu LF, Angst MS, Clark D. Opioid­‑induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479-496. Go to original source... Go to PubMed...
    10. Kotas R. Bolesti hlavy v klinické praxi, Maxdorf 2015.
    11. Mathew NT. Pathophysiology of Chronic Migraine and mode of action of preventive medication. J Headache. 2011; https://doi.org/10.1111/j.1526-4610.2011.01955.x. Go to original source... Go to PubMed...
    12. Nežádal T. Chronická migréna. Neurol. praxi. 2019;20(2): 115-120. Go to original source...
    13. Recober A. Pathopfysiology of Migraine. Continuum (Minneap Minn). Headache. 2021;27(3):586-596, doi: 10.1212/CON.0000000000000983. Go to original source... Go to PubMed...
    14. Silberstein S, Lipton R, Sliwinski M. Classification of daily and near­‑daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871-875. Go to original source... Go to PubMed...
    15. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50 s. J Headache Pain. 2016;17(1):104. Go to original source... Go to PubMed...
    16. Tepper D. Headache Tooolbox. J. Headache Pain. 2020;1037-1039. doi: 10.1111/head.13791. Go to original source... Go to PubMed...
    17. Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic, DiS. 2015;6(3):115-123. doi: 10.1177/2040622315579627. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.